Blog

Therapeutic potential of drug interventions on microglia in ALS

Dr. Susanne Petri, Hannover Medical School, Department of Neurology, in Hannover, Germany presented progress on her project...

Researchers develop ultra-high-performance method to analyze oxylipins

NDR contributed to the work that was published by Dr. Adriano Chaves-Filho and the Dr. Sayuri Miyamoto team. To profile oxylipins in...

NDR starts clinical trial with TVALA

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS....

NDR White Paper Issue 23: Horses to Humans thymopentin has value

Levamisole and thymopentin, the link in treating ALS

First Biomarkers Identified to Measure ALS Disease Progression and Therapeutic Response

https://www.houstonmethodist.org/leading-medicine-blog/articles/2022/sep/first-biomarkers-identified-to-measure-als-disease-progression-a...

Innovate Indiana recognizes Dr. Chandler Walker for secretome work

Indiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and...

ATP and ALS

NDR publishes novel study

The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R...